MX367260B - Tabletas de rucaparib de dosificación elevada. - Google Patents

Tabletas de rucaparib de dosificación elevada.

Info

Publication number
MX367260B
MX367260B MX2017001540A MX2017001540A MX367260B MX 367260 B MX367260 B MX 367260B MX 2017001540 A MX2017001540 A MX 2017001540A MX 2017001540 A MX2017001540 A MX 2017001540A MX 367260 B MX367260 B MX 367260B
Authority
MX
Mexico
Prior art keywords
rucaparib
high dosage
tablet
dosage strength
strength tablets
Prior art date
Application number
MX2017001540A
Other languages
English (en)
Spanish (es)
Other versions
MX2017001540A (es
Inventor
Etter Jeffrey
Original Assignee
Clovis Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clovis Oncology Inc filed Critical Clovis Oncology Inc
Publication of MX2017001540A publication Critical patent/MX2017001540A/es
Publication of MX367260B publication Critical patent/MX367260B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2017001540A 2014-08-22 2015-08-17 Tabletas de rucaparib de dosificación elevada. MX367260B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462040849P 2014-08-22 2014-08-22
US201562101739P 2015-01-09 2015-01-09
PCT/US2015/045522 WO2016028689A1 (en) 2014-08-22 2015-08-17 High dosage strength tablets of rucaparib

Publications (2)

Publication Number Publication Date
MX2017001540A MX2017001540A (es) 2017-05-11
MX367260B true MX367260B (es) 2019-08-12

Family

ID=55347324

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001540A MX367260B (es) 2014-08-22 2015-08-17 Tabletas de rucaparib de dosificación elevada.

Country Status (23)

Country Link
US (3) US9987285B2 (2)
EP (1) EP3182975B1 (2)
JP (3) JP6574477B2 (2)
KR (2) KR102803917B1 (2)
CN (2) CN106794185A (2)
AU (2) AU2015305696B2 (2)
BR (1) BR112017000865A2 (2)
CA (1) CA2955495C (2)
DK (1) DK3182975T3 (2)
ES (1) ES3048688T3 (2)
FI (1) FI3182975T3 (2)
HR (1) HRP20251484T1 (2)
IL (1) IL249946B (2)
LT (1) LT3182975T (2)
MX (1) MX367260B (2)
NZ (1) NZ728392A (2)
PL (1) PL3182975T3 (2)
PT (1) PT3182975T (2)
RS (1) RS67356B1 (2)
RU (1) RU2705156C2 (2)
SG (1) SG11201700265VA (2)
SI (1) SI3182975T1 (2)
WO (1) WO2016028689A1 (2)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
RU2019123406A (ru) 2014-02-05 2019-10-03 Мерк Шарп И Доум Корп. Технология приготовления таблеток для cgrp-активных соединений
AU2015305696B2 (en) 2014-08-22 2019-08-29 Pharma& Schweiz Gmbh High dosage strength tablets of rucaparib
CN106008530B (zh) * 2016-07-24 2018-06-26 石家庄久正生物科技有限公司 一种抗卵巢癌药物Rucaparib关键中间体的制备方法
CN108201534A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种瑞卡帕布口服缓控释药物组合物及其用途
WO2018140377A1 (en) 2017-01-24 2018-08-02 Assia Chemical Industries Ltd. Solid state forms of rucaparib and of rucaparib salts
CN110944638A (zh) 2017-03-27 2020-03-31 特沙诺有限公司 尼拉帕尼组合物
TWI843707B (zh) * 2017-09-26 2024-06-01 美商提薩羅有限公司 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物
WO2019130229A1 (en) 2017-12-28 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing rucaparib
KR20200121800A (ko) 2018-01-05 2020-10-26 싸이브렉사 1, 인크. 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
CN109111454A (zh) * 2018-08-01 2019-01-01 宁波金未生物科技有限公司 一种瑞卡帕布s-樟脑磺酸盐
CN108853030B (zh) * 2018-09-26 2021-10-01 上海朝晖药业有限公司 一种治疗恶性肿瘤的药物制剂及其制备方法
CN111542527A (zh) 2018-12-06 2020-08-14 上海诚妙医药科技有限公司 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途
US11555019B2 (en) 2019-07-10 2023-01-17 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
US20230234938A1 (en) 2020-04-28 2023-07-27 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
EP4182318B1 (en) 2020-07-14 2025-08-27 Assia Chemical Industries Ltd. Solid state forms of rucaparib salts
CN116390712A (zh) 2020-07-29 2023-07-04 阿勒根制药国际有限公司 治疗偏头痛
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
CA3214298A1 (en) 2021-04-08 2022-10-13 Swaroop Kumar Venkata Satya VAKKALANKA Inhibitors of poly(adp-ribose) polymerase
EP4408418A1 (en) 2021-09-27 2024-08-07 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine
JP2024543323A (ja) * 2021-11-10 2024-11-21 クリチテック，インコーポレイテッド ルカパリブ粒子およびその使用
EP4463232A1 (en) 2022-01-11 2024-11-20 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495541B1 (en) 1999-01-11 2002-12-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
CA2520997A1 (en) 2003-03-31 2004-10-14 Stacie Sara Canan-Koch Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
US7531530B2 (en) 2003-07-25 2009-05-12 Cancer Research Technology Limited Therapeutic compounds
MX2007003314A (es) 2004-09-22 2007-08-06 Pfizer Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas.
ATE551345T1 (de) 2004-09-22 2012-04-15 Pfizer Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-on
PT1794163E (pt) 2004-09-22 2010-03-01 Pfizer Método para a preparação de inibidores de poli(adpribose)- polimerases
CA2720744A1 (en) * 2008-04-09 2009-10-15 Lek Pharmaceuticals D.D. Granulation of active pharmaceutical ingredients
EP4166558A1 (en) 2010-02-12 2023-04-19 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one
CN108478577A (zh) * 2012-04-05 2018-09-04 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
AU2015305696B2 (en) 2014-08-22 2019-08-29 Pharma& Schweiz Gmbh High dosage strength tablets of rucaparib

Also Published As

Publication number Publication date
DK3182975T3 (da) 2025-10-20
IL249946B (en) 2020-05-31
SI3182975T1 (sl) 2025-12-31
RS67356B1 (sr) 2025-11-28
AU2015305696A1 (en) 2017-02-02
FI3182975T3 (fi) 2025-11-13
JP2017525712A (ja) 2017-09-07
JP7127101B2 (ja) 2022-08-29
US9987285B2 (en) 2018-06-05
US10130636B2 (en) 2018-11-20
AU2019272064B2 (en) 2021-11-18
CA2955495C (en) 2023-09-19
US20160051561A1 (en) 2016-02-25
AU2015305696B2 (en) 2019-08-29
KR20170043597A (ko) 2017-04-21
WO2016028689A1 (en) 2016-02-25
NZ728392A (en) 2023-06-30
RU2017109139A3 (2) 2019-03-06
CN113209033A (zh) 2021-08-06
CN106794185A (zh) 2017-05-31
US20180200260A1 (en) 2018-07-19
KR102803917B1 (ko) 2025-05-07
BR112017000865A2 (pt) 2017-12-05
EP3182975A4 (en) 2018-04-18
PT3182975T (pt) 2025-10-28
LT3182975T (lt) 2025-11-25
RU2017109139A (ru) 2018-09-24
HRP20251484T1 (hr) 2026-01-02
PL3182975T3 (pl) 2026-02-23
ES3048688T3 (en) 2025-12-11
EP3182975A1 (en) 2017-06-28
AU2019272064A1 (en) 2019-12-19
JP2020002149A (ja) 2020-01-09
JP2021038242A (ja) 2021-03-11
JP6574477B2 (ja) 2019-09-11
EP3182975B1 (en) 2025-10-01
SG11201700265VA (en) 2017-02-27
US20190099430A1 (en) 2019-04-04
KR20230097211A (ko) 2023-06-30
CA2955495A1 (en) 2016-02-25
IL249946A0 (en) 2017-03-30
MX2017001540A (es) 2017-05-11
JP6797980B2 (ja) 2020-12-09
RU2705156C2 (ru) 2019-11-05

Similar Documents

Publication Publication Date Title
MX2017001540A (es) Tabletas de rucaparib de dosificacion elevada.
PH12017500121A1 (en) Tablet formulation of a c-met inhibitor
PH12017500408B1 (en) Heteroaryl compounds as btk inhibitors and uses thereof
PH12017500802B1 (en) Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
CL2016002310A1 (es) Nuevos compuestos bicíclicos.
MA39986A (fr) Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
SI3152212T1 (sl) Radioaktivno označeni derivati 2-amino-6-fluoro-N-(5-fluoro-piridin-3-IL)-pirazolo (1,5-A)pirimidin-3- karboksamidne spojine, koristni kot inhibitor kinaze ATR, priprava navedene spojine in njene različne trdne oblike
IL248546B (en) A multi-fluorinated compound as an inhibitor of proton tyrosine kinase
SI3077397T1 (sl) 2-amino-6-fluoro-N-(5-fluoro-piridin-3-IL)pirazolo(1,5-A)pirimidin-3- karboksamidna spojina, koristna kot inhibitor kinaze ATR, njena priprava, različne trdne oblike in njeni radioaktivno označeni derivati
WO2017075629A3 (en) Wee 1 kinase inhibitors and methods of making and using the same
UA111804C2 (uk) ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК ІНГІБІТОРИ ЯНУС-ЗАЛЕЖНИХ КІНАЗ (JAK)
SI3227297T1 (sl) 4,6-substituirani-pirazolo(1,5-A)pirazini kot inhibitorji Janus kinaze
CL2013002063A1 (es) Compuestos derivados de pirrolo(piridina, pirimidina o pirazina), inhibidores de serina/trionina cinasa; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer, infecciones inflamaciones y enfermedades autoinmune.
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
CL2016000496A1 (es) Compuestos derivados de 1,2,4-triazolo[1,5-a]-piridina, inhibidores de una janus cinasa, tal como jak1; composiciones farmacológicas; útiles para el tratamiento de enfermedades inflamatorias.
WO2016073771A3 (en) Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors
GEP20186934B (en) Quinolizinone derivatives as pi3k inhibitors
SI3596080T1 (sl) Farmakološko aktivni aliciklični-substituirani pirazolo-(1,5-a)pirimidinski derivati
PL3102187T3 (pl) Stabilne kompozycje farmaceutyczne zawierające sitagliptynę w postaci tabletek o natychmiastowym uwalnianiu
MX2017008931A (es) Formulaciones farmaceuticas de xantina o derivados de xantina.
PH12016502540B1 (en) Pharmaceutical dosage forms
HK1236034A1 (en) Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
HK1236035A1 (en) Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases

Legal Events

Date Code Title Description
FG Grant or registration